| Class |
Group |
Item |
Detail |
Description |
State Contract |
|
278
|
300
|
000
|
0000
|
Antineoplastic Drugs, Miscellaneous
|
|
|
278
|
300
|
300
|
0000
|
Interferon Alfa-2a, Usp
|
|
|
278
|
300
|
300
|
0100
|
Injection; 3 Million Un; 1ml Vial W/
|
|
|
278
|
300
|
300
|
0200
|
Injection; 5 Million Un; 1ml Vial W/
|
|
|
278
|
300
|
300
|
0250
|
Injection; 9 Million Un; 1ml Vial W/
|
|
|
278
|
300
|
300
|
0300
|
Injection; 18 Million Un; 1ml Vial W/
|
|
|
278
|
300
|
300
|
1100
|
Injection; 3 Million Un; Syringe; 1 Box
|
|
|
278
|
300
|
300
|
1200
|
Injection; 6 Million Un; Syringe; 1 Box
|
|
|
278
|
300
|
300
|
1250
|
Injection; 9 Million Un; Syringe; 1 Box
|
|
|
278
|
300
|
320
|
0000
|
Interferon Alfa-2b
|
|
|
278
|
300
|
320
|
0250
|
Injection, 3 Million Unit Vial, 6 Vials/
|
|
|
278
|
300
|
320
|
0258
|
Injection, 3 Million Un/0.5mll Vials
|
|
|
278
|
300
|
320
|
0260
|
Injection, 3 Million Un/0.5mll Vials
|
|
|
278
|
300
|
320
|
0277
|
Injection, 5 Million Un/0.5mll Vials
|
|
|
278
|
300
|
320
|
0300
|
Injection, 25 Million Unit Vial.
|
|
|
278
|
300
|
330
|
0000
|
Interferon Alfacon-1, Ups
|
|
|
278
|
300
|
330
|
0100
|
Injection, 9mcg; 0.3ml Single-Dose
|
|
|
278
|
300
|
330
|
0150
|
Injection, 9mcg; 0.3ml Single-Dose
|
|
|
278
|
300
|
330
|
0200
|
Injection, 15mcg; 0.5ml Single-Dose
|
|
|
278
|
300
|
330
|
0250
|
Injection, 15mcg; 0.5ml Single-Dose
|
|
|
278
|
300
|
340
|
0000
|
Interferon Alfa-2b, Recombinate,
|
|
|
278
|
300
|
340
|
0110
|
Injection, Capsule; 3mun/0.5ml Vails
|
|
|
278
|
300
|
340
|
0140
|
Injection, Capsule; 6 3un/0.5ml Vails
|
|
|
278
|
300
|
340
|
0150
|
Injection, Capsule; 18mun (3mun/0.5ml)
|
|
|
278
|
300
|
340
|
0170
|
Injection, Capsule; 6mun/0.5ml Vails
|
|
|
278
|
300
|
350
|
0000
|
Gemcitabine, Usp
|
|
|
278
|
300
|
350
|
0100
|
Powder For Injection; 20mcg/Ml;
|
|
|
278
|
300
|
600
|
0000
|
Dacarbazne, Usp
|
|
|
278
|
300
|
600
|
0050
|
Powder For Injection, 200mg/Vial
|
|
